Rasilamlo (aliskiren hemifumarate;amlodipine besilate)
- Region
- 🇪🇺 EU
- Active substance
- aliskiren hemifumarate;amlodipine besilate
- Company
- Novartis Europharm Ltd
- Status
- Withdrawn
- Therapeutic area
- Hypertension
- EU approval
- Thu 14 Apr 2011
- Application
- EMEA/H/C/002073
- ATC
- C09XA53
- Official record
- www.ema.europa.eu
Indication
Rasilamlo is indicated for the treatment of essential hypertension in adult patients whose blood pressure is not adequately controlled with aliskiren or amlodipine used alone.
Regulatory milestones
No milestones recorded in the last year.
Follow Rasilamlo
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.